论文部分内容阅读
目的探讨海鞘提取物治疗糖尿病及并发心血管疾病的有效性及其作用机制。方法用链尿菌素建立大鼠糖尿病模型,给予海鞘提取物干预,检测血糖和血浆内皮素-1(endothelin-1,ET-1)含量。结果链脲菌素腹腔注射1周后,其血糖水平均显著高于正常对照组,应用于本次实验的糖尿病大鼠的血糖含量均>8.1 mmol/L。连续给药干预4周后,糖尿病模型对照组血糖明显高于空白对照组(P<0.01),海鞘干预组明显低于糖尿病模型对照组(P<0.01)。糖尿病模型对照组大鼠血浆ET-1含量明显高于正常对照组(P<0.01),海鞘干预组的血浆ET-1含量明显低于糖尿病模型对照组(P<0.01)。结论海鞘提取物对链尿菌素所致大鼠糖尿病具有降糖作用;对糖尿病引起的ET-1升高有抑制作用。
Objective To investigate the effectiveness and mechanism of ascidian extract in the treatment of diabetes mellitus and cardiovascular diseases. Methods Streptozotocin was used to establish a rat model of diabetes mellitus. The changes of blood glucose and endothelin-1 (ET-1) levels were detected by the intervention of sea squirt extract. Results After 1 week of intraperitoneal injection of streptozotocin, the blood glucose level of streptozotocin was significantly higher than that of the normal control group. The blood glucose level of diabetic rats used in this experiment was> 8.1 mmol / L. The blood glucose in diabetic model control group was significantly higher than that in blank control group (P <0.01) after four weeks of continuous administration, and significantly lower in diabetic group than in control group (P <0.01). The content of ET-1 in the diabetic model control group was significantly higher than that in the normal control group (P <0.01). The plasma ET-1 level in the sea squirt intervention group was significantly lower than that in the diabetic model control group (P <0.01). Conclusion Ascidian extract has a hypoglycemic effect on streptozotocin-induced diabetic rats and inhibits the elevated ET-1 induced by diabetes.